Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…Abstract Number: 039 • 2023 Pediatric Rheumatology Symposium
Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts up to 15% of all patients with JIA and is distinctfrom the other disease categories due to the…Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…Abstract Number: 091 • 2023 Pediatric Rheumatology Symposium
Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…Abstract Number: 093 • 2023 Pediatric Rheumatology Symposium
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are a group vasculitides with significant morbidity and mortality requiring toxic therapy. Clinical trials in adults…Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…Abstract Number: 028 • 2023 Pediatric Rheumatology Symposium
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by symmetric proximal muscle weakness, distinct rash, and a risk for calcinosis. Systemic immunosuppression is needed. Evidence is limited…Abstract Number: 0077 • ACR Convergence 2022
Rheumatoid Arthritis – Are We Getting to Target?
Background/Purpose: Low disease activity (LDA) is a key goal in treating Rheumatoid arthritis, but implementing the treat to target approach in clinical practice has been…Abstract Number: 0285 • ACR Convergence 2022
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…Abstract Number: 0722 • ACR Convergence 2022
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…Abstract Number: 1084 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…Abstract Number: 1388 • ACR Convergence 2022
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
Background/Purpose: The Rheumatic Disease Comorbidity Index (RDCI) was designed to quantify comorbidity burden for risk stratification of health outcomes in patients with rheumatic disease. Developed…Abstract Number: 1847 • ACR Convergence 2022
Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)
Background/Purpose: Incorporating patient perspectives of their disease state is needed for disease activity assessment in adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO). The…Abstract Number: 2105 • ACR Convergence 2022
Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
Background/Purpose: Frailty is associated with increased risk of adverse health outcomes in SLE. Multiple definitions for frailty exist, and how best to measure frailty in…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 49
- Next Page »